JointHealth™ express April 27, 2009
Health Canada has approved a new medication for use in the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Golimumab (Simponi®) was issued its Notice of Compliance (NOC) on April 7, 2009.
This is great news for Canadians living with these forms of inflammatory arthritis.
Golimumab is a biologic response modifier targeting the TNF-alpha molecule, also known as a TNF-blocker. Golimumab will be used to treat people with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who do not respond sufficiently to a trial of traditional Disease Modifying Anti-Rheumatic Drugs (DMARDs), or combinations of DMARDs.
There are now four TNF-blockers approved for use in the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis in Canada. Each of the four works in the body a different way, and there is no way to predict which one may work in a given person. Golimumab is the first TNF-blocker that is administered by monthly injection.
To learn if golimumab or another inflammatory arthritis treatment may be helpful to you, please speak to your rheumatologist or other health care provider helping you to manage your disease.
To view the Notice of Compliance, please click here and search for "Simponi".
Health Canada has approved a new medication for use in the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Golimumab (Simponi®) was issued its Notice of Compliance (NOC) on April 7, 2009.
This is great news for Canadians living with these forms of inflammatory arthritis.
Golimumab is a biologic response modifier targeting the TNF-alpha molecule, also known as a TNF-blocker. Golimumab will be used to treat people with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who do not respond sufficiently to a trial of traditional Disease Modifying Anti-Rheumatic Drugs (DMARDs), or combinations of DMARDs.
There are now four TNF-blockers approved for use in the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis in Canada. Each of the four works in the body a different way, and there is no way to predict which one may work in a given person. Golimumab is the first TNF-blocker that is administered by monthly injection.
To learn if golimumab or another inflammatory arthritis treatment may be helpful to you, please speak to your rheumatologist or other health care provider helping you to manage your disease.
To view the Notice of Compliance, please click here and search for "Simponi".
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.